
Stimulating insulin secretion from the pancreas when blood glucose rises
Inhibiting glucagon release, which helps prevent excess glucose production by the liver
Slowing gastric emptying, leading to prolonged digestion and steadier blood sugar levels

Available as Victoza (for diabetes) and Saxenda (for weight management)
Available as Ozempic (for diabetes) and Wegovy (for weight management)
Available as Mounjaro (for diabetes and weight management)
GLP-1 agonists support blood sugar control by enhancing insulin secretion in response to meals and by reducing how much glucose the liver releases into the bloodstream. These medications are typically used when oral diabetes treatments like metformin do not fully manage a patient’s glucose levels. In addition, some GLP-1 agonists have demonstrated the ability to lower the risk of heart related complications among people with type 2 diabetes who already have cardiovascular conditions.
Among people without diabetes, medications such as Wegovy and Saxenda are GLP-1 agonists that have FDA approval for weight loss. They help by enhancing satiety and lowering hunger signals, making it easier to reduce food intake without feeling deprived. Clinical studies indicate that pairing these drugs with nutrition and activity changes can produce strong and lasting weight loss results.
GLP-1 receptor agonists support blood sugar control by enhancing insulin secretion in response to food and decreasing glucagon output from the liver. This coordinated effect helps smooth out blood glucose levels and improve long term glycemic management. Their glucose dependent mechanism means the risk of low blood sugar is much lower than with many older diabetes treatments.
An important benefit of GLP-1 therapy is its proven ability to promote durable weight loss and support ongoing weight control. These medications slow gastric emptying and activate brain pathways that heighten the sense of fullness, which helps reduce hunger and makes calorie reduction more achievable in daily life. Evidence from clinical studies shows that liraglutide, semaglutide, and tirzepatide can deliver strong and lasting weight loss results when used in combination with lifestyle modification.



GLP-1/GIP co-agonists simultaneously activate GLP-1 and GIP receptors, leading to more efficient insulin secretion and stronger appetite suppression than GLP-1 monotherapy. By harnessing two incretin hormones, these agents can deliver deeper improvements in blood sugar control and hunger management, offering new possibilities in diabetes and obesity care.
GLP-1/glucagon co-agonists work on GLP-1 and glucagon receptors together to boost metabolic rate and fat loss, helping patients lose weight while maintaining lean muscle.

